Global Cancer Biomarkers Market Opportunity Analysis and Industry Forecast till 2031: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), By P

Global Cancer Biomarkers Market Opportunity Analysis and Industry Forecast till 2031: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), By Profiling Technologies (Omics Technology, Imaging Technologies, Immunoassays, Bioinformatics, Cytogenetics), By Application (Diagnostics, Research & Development, Prognostics, Risk Assessments, Others); and By Region

The global cancer biomarkers market size was USD 13.4 billion in 2021 and it is anticipated to reach USD 63.6 billion by 2031, growing at a CAGR of 16.9% from 2022-2031.


Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body, estimated by collecting samples such as stool, tumor tissue, blood, urine, or other tissues or bodily fluids. Biomarkers may be formed by the cancer tissue itself or by other cells in the body in response to cancer. They enhance cancer detection and assist in high-speed noninvasive diagnosis using genomics and proteomics.

Global Cancer Biomarkers Market Scope and Structure AnalysisMarket Trends and Drivers

The key factor boosting the growth of the market is rising technological advancements in the development of cancer biomarkers. The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to great extent.


Similarly, the growing preference for personalized medicine is also boosting the growth of the market. Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. So, the field of personalized medicine is likely to offer potential growth opportunities for players operating in the cancer biomarkers market.

Market Restraints and Challenges

The key factor hampering the growth of the global cancer biomarker market is technical issues related to sample collection and storage. The sample collection is one of the key issues for service providers, followed by access to these samples. Stringent quality control of this sample is essential, and they need to be stored under the right conditions to avoid any loss. Additionally, different samples are required for risk detection, screening, diagnosis, and monitoring processes. Likewise, challenges associated with cancer biomarker validation is also hindering the growth of the market. The cancer biomarker validation process comprises evaluation assays or measuring performance characteristics like sensitivity, specificity, and reproducibility. Validation is critical for establishing cancer biomarkers as reliable tool to support development, medical care, and biopharma investment decisions.

Global Cancer Biomarkers Market Segmentation

The report analyses the global cancer biomarkers market based on biomarker type, cancer type, profiling technologies, application, and region.

Global Cancer Biomarkers Market by Biomarker Type

Based on biomarker type, it is segmented into protein biomarkers, genetic biomarkers, and others. The protein biomarker segment is likely to dominate the market during the forecast period. The key factors such as increasing research on cancer biomarkers are propelling the growth of the market.

Global Cancer Biomarkers Market by Cancer Type

Based on cancer type, it is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The breast cancer segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing incidence of cancer across the globe are boosting the growth of the market.

Global Cancer Biomarkers Market by Profiling Technologies

Based on profiling technologies, it is segmented into omics technologies, imaging technologies, immunoassays, bioinformatics, and cytogenetics. The omics technologies are estimated to dominate the market during the forecast period. The key factors such as the increased use of cancer biomarkers for new developments are boosting the growth of this segment.

Global Cancer Biomarkers Market by Application

Based on application, it is segmented into, it is segmented into diagnostics, research & development, prognostics, risk assessments, and others. The diagnostic segment is likely to dominate the market during the forecast period. The factors such as an increase in the application of cancer biomarkers for companion diagnostics will boost the market growth during the forecast period.

Geographical Analysis of Global Cancer Biomarkers Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the global cancer biomarkers market. The North American cancer biomarkers market’s growth can be attributed to the correlation between the rising population and increased research activities.

Major Players in Global Cancer Biomarkers Market

The major key players in the cancer biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

COVID-19 Analysis

It was primarily thought novel coronavirus (covid-19, sars-cov-2) was majorly a respiratory disorder, but as larger numbers of patients contracted the virus, it rapidly became clear it had many physiological manifestations. The impact of covid-19 goes well beyond the lungs to impact the cardiovascular system and cause complications in the kidneys, brain, and other organs. Critical patients frequently require care from a multidisciplinary care team. Moreover, COVID patients with comorbidities were more likely to have severe symptoms requiring hospitalization. Yet, patients with pre-existing cardiovascular diseases suffer the highest mortality rate of all COVID patients.


The implications of decreased testing are of great concern for many stakeholders, comprising physicians, hospitals, laboratories, pharmaceutical companies, and, most probably, patients. Diagnosis and cancer biomarker testing is the earliest indicators of treatment, which may comprise new targeted therapies with the potential to improve patient results; they should not be delayed. Routine screening for breast, ovarian and colorectal cancer also needs to be done timely as they constitute effective preventive and early detection measures. The pandemic has significantly and negatively altered how cancer patients are being diagnosed and treated in the upcoming years.

Recent Developments

• February 2022, Onco DNA introduced the Onco Deep Solid Tumor Biomarker Test Kit. The Onco Deep kit, which comprises Twist Bioscience’s enrichment and library preparation solutions, will give labs a complete and reliable solution for performing comprehensive NGS analysis of tumor samples.
• April 2021, F. Hoffmann-La Roche Ltd., launched Elecsys Anti-p53 immunoassay to assist in the diagnosis of various cancer types.
• December 2020, Thermo Fisher Scientific (US) received FDA approval for NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
• April 2020, Qiagen N.V. launched the therascreen BRAF test as a companion diagnostic to a BRAFTOVI-based regimen in metastatic colorectal cancer.
• May 2019, Biotech Support Group (BSG) and Leiden University Medical Center (LUMC) have established a research partnership to identify stromal conditioning biomarkers in Cancer.

Frequently Asked Questions

Q. How big is the cancer biomarkers market?Ans. The global cancer biomarkers market size was USD 13.4 Million in 2021 and is anticipated to reach USD 63.6 Million in 2031, growing at a rate of 16.9% from 2022 to 2031.
Q. What is the cancer biomarkers market growth rate?Ans. The growth rate of the cancer biomarkers market is 16.9% from 2022 to 2031.
Q. Which Ans. North America holds a major market share of the cancer biomarkers market in 2021.
Q. Which segment accounted for the largest cancer biomarkers market share?Ans. By application, the diagnostic segment accounted for the largest cancer biomarkers market share
Q. Who are the key players in the breath analyzer market?Ans. The global cancer biomarkers market report includes players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).
Q. What are the factors driving the cancer biomarkers market growth?Ans. The major factors driving the growth of the market are the increasing incidences of cancer.
Q. What are the key growth strategies of cancer biomarkers market players?Ans. The key growth strategies of cancer biomarkers market players are product launch and product approval.
Q. Which Ans. The Asia-Pacific region will provide more business opportunities for cancer biomarkers market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.